Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma.
María José Juan FitaM JoseR SilverioV FedericoC IsabelO-A MartinB InmaculadaC CristinaH-C JuliaT M DoloresG JoseP PaolaDel P NievesA VicentB SaraM SaraL JuliánS ManuelM M Del CarmenC M ÁngelG VicentePublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
Benefit/risk profile of nivolumab in Eastern-Spanish real-world population with mRCC after tyrosine-kinase inhibitors was consistent with prior real-life studies reported as well as pivotal study.